Inflammatory Markers and Cardiovascular Patient Outcomes

描述（由申请人提供）：候选人是德克萨斯大学休斯顿健康科学中心（UT-休斯顿）护理学院的副教授，目前是进行心血管研究的跨学科研究团队的成员。作为遗传学和高血压的博士后研究员，她开始参加NIH资助的临床研究课程，她将在拟议的K奖期间完成。长期目标是开发一种模型，允许继续探索诊断为心血管疾病的患者的遗传，生化和环境风险因素。教育的具体目标是增加有关心血管疾病的知识，这将激发生化标志物和相关基因的新研究假设，并增加大型临床队列研究的设计和分析知识，这将提高未来赠款的质量。UT休斯顿提供的环境支持包括通过人类遗传学中心提供的实验室支持;通过UT休斯顿医学院临床研究课程提供的教育支持;以及通过TexGen资源访问患者，摘要和长期随访。该奖项将支持一项试点研究，以探索炎症标志物和相关候选基因变异的预后价值，以预测心血管疾病患者的不良结局。该研究的具体目的是确定以下预后价值：1）预测急性冠状动脉综合征（ACS）时间和严重程度的新型生物标志物，后续再灌注干预的结果（支架置入术、血管成形术或心脏搭桥手术）、死亡、中风和心肌梗死（MI），并测试与人口统计学/生活方式和传统临床预测因素的相互作用;和2）编码目标1中鉴定的新生物标志物的基因中的DNA序列变异，通过评估序列变异和生物标志物的相互作用来预测ACS结果的时间和严重性：随后的再灌注干预、死亡、中风和MI，并测试与人口统计学/生活方式和传统临床预测因子的相互作用。拟议的K奖将允许保护时间需要发展的知识和技能的设计，性能和分析的临床研究;发展心血管生物标志物的临床知识;并进行拟议的试点研究在得克萨斯州医学中心。试验数据将作为RO 1应用的初步数据。

DESCRIPTION (provided by applicant): The candidate, an Associate Professor at the University of Texas Health Science Center at Houston (UT-Houston) School of Nursing, is currently a member of an interdisciplinary research team that conducts cardiovascular research. As a postdoctoral fellow in genetics and hypertension, she began participating in an NIH-funded Clinical Research Curriculum that she will complete during the proposed K Award. The long-term goal is to develop a model that will allow continued exploration of genetic, biochemical, and environmental risk factors in patients diagnosed with cardiovascular disease. Educational specific aims are to increase knowledge about cardiovascular disease that will stimulate new research hypotheses of the biochemical markers and related genes, and to increase knowledge in the design and analysis of large clinical cohort studies that will augment the quality of future grants. Environmental support available at UT-Houston includes laboratory support through the Human Genetics Center; educational support through the UT-Houston Medical School Clinical Research Curriculum; and access to patients, abstracting, and long-term follow-up through the TexGen Resource. The Award will support a pilot study to explore the prognostic value of inflammatory markers and related candidate gene variation to predict adverse outcomes in patients with cardiovascular disease. Specific aims of the research are to identify the prognostic value of: 1) novel biomarkers to predict the timing and severity of acute coronary syndrome (ACS), outcomes of: subsequent reperfusion interventions (stent placement, angioplasty, or cardiac bypass surgery), death, stroke, and myocardial infarction (MI), and to test for interactions with demographic/lifestyle and traditional clinical predictors; and 2) DNA sequence variation in the genes encoding the novel biomarkers identified in Aim 1, by assessing the interaction of the sequence variations and biomarkers to predict the timing and severity of the ACS outcomes of: subsequent reperfusion interventions, death, stroke, and MI, and to test for interaction with demographic/lifestyle and traditional clinical predictors. The proposed K award will allow the protected time needed to develop knowledge and skills in design, performance, and analysis of clinical research; to develop clinical knowledge of cardiovascular biomarkers; and to conduct the proposed pilot research in the Texas Medical Center. The pilot data will serve as preliminary data for an RO1 application.